# US 2009/0156621 A1 · Hcv inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0156621 A1
- Document ID: US20090156621A1
- Status: Published application
- Kind: A1
- Application number: 11/719,903
- Filed: 2005-11-14
- Published: 2009-06-18
- Earliest claimed: 2004-11-22
- Inventors: Kristian Gudmundsson
- Web page: https://patentgrep.com/patent/US20090156621A1

## CPC

- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/403: condensed with carbocyclic rings, e.g. carbazole
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to compounds that are useful in the treatment of viruses belonging to Flaviviridae, including flaviviruses, pestiviruses, and hepaciviruses. The invention includes compounds useful for the treatment or prophylaxis of dengue fever, yellow fever, West Nile virus, and HCV.

## Claims

### Claim 1

A method for the treatment or prophylaxis of Flaviviridae viruses through administration of a compound of formula (I):
wherein
n is 0, 1, or 2;
X is NH, O, or S(O)m;
each R is the same or different and is independently selected from the group consisting
of halogen, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, —R10cycloalkyl, Ay, —NHR10Ay, Het, —NHHet, —NHR10Het, —OR2, —OAy, —OHet, —R10OR2, —NR2R3, —NR2Ay, —R10NR2R3, —R10NR2Ay, —R10C(O)R2, —C(O)R2, —CO2R2, —R10CO2R2, —C(O)NR2R3, —C(O)Ay, —C(O)NR2Ay, —C(O)Het, —C(O)NHR10Het, —R10C(O)NR2R3, —C(S)NR2R3, —R10C(S)NR2R3, —R10NHC(NH)NR2R3, —C(NH)NR2R3, —R10C(NH)NR2R3, —S(O)2NR2R3, —S(O)2NR2Ay, —R10SO2NHCOR2, —R10SO2NR2R3, —R10SO2R2, —S(O)mR2, cyano, nitro, or azido;
each R1 is the same or different and is independently selected from the group consisting of halogen, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, —R10 cycloalkyl, Ay, —NHR10Ay, Het, —NHHet, —NHR10Het, —OR2, —OAy, —OHet, —R10OR2, —NR2R3, —NR2Ay, —R10NR2R3, —R10NR2Ay, —R10C(O)R2, —C(O)R2,
—CO2R2, —R10CO2R2, —C(O)NR2R3, —C(O)Ay, —C(O)NR2Ay, —C(O)Het, —C(O)NHR10Het, —R10C(O)NR2R3, —C(S)NR2R3, —R10C(S)NR2R3, —R10NHC(NH)NR2R3, —C(NH)NR2R3, —R10C(NH)NR2R3, —S(O)2NR2R3, —S(O)2NR2Ay, —R10SO2NHCOR2, —R10SO2NR2R3, —R10SO2R2, —S(O)mR2, cyano, nitro, or azido;
each m independently is 0, 1, or 2;
each R10 is the same or different and is independently selected from alkylene, cycloalkylene, alkenylene, cycloalkenylene, and alkynylene;
p and q are each independently selected from 0, 1, 2, 3, 4, or 5;
each of R2 and R3 are the same or different and are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, —R10cycloalkyl, —R10OH, —R10(OR10)w, and —R10NR4R5;
w is 1-10;
each of R4 and R5 are the same or different and are independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, cycloalkenyl, and alkynyl;
Ay represents an aryl group;
Het represents a 5- or 6-membered heterocyclyl or heteroaryl group;
ring A is aryl or heteroaryl; and
pharmaceutically acceptable salts and solvates.

### Claim 2 (depends on 1)

The method of claim 1 wherein the virus is a flaviviruses, a pestiviruses, or a hepaciviruses.

### Claim 3 (depends on 2)

The method of claim 2 wherein the virus is associated with a human disease selected from dengue fever, yellow fever, west nile virus, and HCV.

### Claim 4 (depends on 3)

The method of claim 3 wherein the human disease is HCV infection.

### Claim 5 (depends on 1)

The method of claim 1 wherein X is NH.

### Claim 6 (depends on 1)

The compound of claim 1 wherein alkyl is C1-C6 alkyl, alkoxy is C1-C6 alkoxy, and haloalkyl is C1-C6 haloalkyl.

### Claim 7 (depends on 1)

The method of claim 1 wherein at least p or q is not 0.

### Claim 8 (depends on 1)

The method of claim 1 wherein both p and q are each 1.

### Claim 9 (depends on 1)

The method of claim 1 wherein n is 1 or 2.

### Claim 10 (depends on 9)

The method of claim 9 wherein n is 1.

### Claim 11 (depends on 1)

The method of claim 1 wherein R is selected from halogen, alkyl, haloalkyl, cycloalkyl, —R10cycloalkyl, Ay, Het, —OR2, —R10OR2, —NR2R3, —COR2, —CO2R2, —CONR2R3, —S(O)2NR2R3, cyano, nitro, or azido.

### Claim 12 (depends on 11)

The method of claim 11 wherein R is selected from halogen, alkyl, haloalkyl, cycloalkyl, —R10cycloalkyl, Ay, Het, —OR2, —R10OR2, —NR2R3, —COR2, —CONR2R3, —S(O)2NR2R3, or cyano.

### Claim 13 (depends on 12)

The method of claim 12 wherein R is selected from halogen, alkyl, or haloalkyl.

### Claim 14 (depends on 13)

The method of claim 13 wherein R is selected from Cl or Br.

### Claim 15 (depends on 13)

The method of claim 13 wherein R is substituted para to the depicted N atom.

### Claim 16 (depends on 1)

The method of claim 1 wherein R1 selected from halogen, alkyl, haloalkyl, Ay, Het, —OR2, —R10OR2, —NR2R3, —COR2, —CO2R2, —CONR2R3, —S(O)2NR2R3, —S(O)mR2, cyano, nitro, or azido.

### Claim 17 (depends on 16)

The method of claim 16 wherein R1 is selected from halogen, alkyl, haloalkyl, —OR2, cyano, or nitro.

### Claim 18 (depends on 17)

The method of claim 17 wherein R1 is selected from halogen, alkyl, haloalkyl, —OR2.

### Claim 19 (depends on 18)

The method of claim 18 wherein q is 1 or 2.

### Claim 20 (depends on 1)

The method of claim 1 wherein the A ring is aryl.

### Claim 21 (depends on 20)

The method of claim 20 wherein the A ring is phenyl.

### Claim 22 (depends on 1)

The method of claim 1 wherein the A ring is heteroaryl.

### Claim 23 (depends on 22)

The method of claim 22 wherein the heteroaryl is pyrimidinyl, pyridyl, or benzothiazolyl.

### Claim 24 (depends on 23)

The method of claim 23 wherein the heteroaryl is pyrimidinyl or pyridyl.

### Claim 25 (depends on 24)

The method of claim 24 wherein q is 0, 1, or 2.

### Claim 26 (depends on 1)

The method of claim 1 wherein when p is not 0, then each R is the same or different and is independently selected from the group consisting of halogen, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, —R10cycloalkyl, Ay, —NHR10Ay, Het, —NHHet, —NHR10Het, —R10OR2, —NR2R3, —NR2Ay, —R10NR2R3, —R10NR2Ay, —R10C(O)R2, —C(O)R2, —CO2R2, —R10CO2R2, —C(O)NR2R3, —C(O)Ay, —C(O)NR2Ay, —C(O)Het, —C(O)NHR10Het, —R10C(O)NR2R3, —C(S)NR2R3, —R10C(S)NR2R3, —R10NHC(NH)NR2R3, —C(NH)NR2R3, —R10C(NH)NR2R3, —S(O)2NR2R3, —S(O)2NR2Ay, —R10SO2NHCOR2, —R10SO2NR2R3, —R10SO2R2, —S(O)mR2, cyano, nitro, or azido.

### Claim 27

A use of a compound of formula (I):
wherein:
n is 0, 1, or 2;
X is NH, O, or S(O)m;
each R is the same or different and is independently selected from the group consisting
of halogen, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, —R10cycloalkyl, Ay, —NHR10Ay, Het, —NHHet, —NHR10Het, —OR2, —OAy, —OHet, —R10OR2, —NR2R3, —NR2Ay, —R10NR2R3, —R10NR2Ay, —R10C(O)R2, —C(O)R2, —CO2R2, —R10CO2R2, —C(O)NR2R3, —C(O)Ay, —C(O)NR2Ay, —C(O)Het, —C(O)NHR10Het, —R10C(O)NR2R3, —C(S)NR2R3, —R10C(S)NR2R3, —R10NHC(NH)NR2R3, —C(NH)NR2R3, —R10C(NH)NR2R3, —S(O)2NR2R3, —S(O)2NR2Ay, —R10SO2NHCOR2, —R10SO2NR2R3, —R10SO2R2, —S(O)mR2, cyano, nitro, or azido;
each R1 is the same or different and is independently selected from the group consisting of halogen, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, —R10 cycloalkyl, Ay, —NHR10Ay, Het, —NHHet, —NHR10Het, —OR2, —OAy, —OHet, —R10OR2, —NR2R3, —NR2Ay, —R10NR2R3, —R10NR2Ay, —R10C(O)R2, —C(O)R2, —CO2R2, —R10CO2R2, —C(O)NR2R3, —C(O)Ay, —C(O)NR2Ay, —C(O)Het, —C(O)NHR10Het, —R10C(O)NR2R3, —C(S)NR2R3, —R10C(S)NR2R3, —R10NHC(NH)NR2R3, —C(NH)NR2R3, —R10C(NH)NR2R3, —S(O)2NR2R3, —S(O)2NR2Ay, —R10SO2NHCOR2, —R10SO2NR2R3, —R10SO2R2, —S(O)mR2, cyano, nitro, or azido;
each m independently is 0, 1, or 2;
each R10 is the same or different and is independently selected from alkylene, cycloalkylene, alkenylene, cycloalkenylene, and alkynylene;
p and q are each independently selected from 0, 1, 2, 3, 4, or 5;
each of R2 and R3 are the same or different and are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, —R10cycloalkyl, —R10OH, —R10(OR10)w, and —R10NR4R5;
w is 1-10;
each of R4 and R5 are the same or different and are independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, cycloalkenyl, and alkynyl;
Ay represents an aryl group;
Het represents a 5- or 6-membered heterocyclyl or heteroaryl group;
ring A is aryl or heteroaryl; and
pharmaceutically acceptable salts and solvates thereof, in the manufacture of a medicament for use in the treatment or prophylaxis of viruses belonging to Flaviviridae.

### Claim 28 (depends on 27)

The use according to claim 27 wherein the virus is a flavivirus, a pestivirus, or a hepacivirus.

### Claim 29 (depends on 28)

The use according to claim 28 wherein the virus is associated with a human disease or condition selected from dengue fever, yellow fever, west nile virus, or HCV.

### Claim 30 (depends on 29)

The use according to claim 29 wherein the condition or disease is HCV.
